Warner-lambert Company

Pfizer Corporation

Development Finance Corporation of New Zealand

Genentech, Inc.

Xenova Limited

Vetdc, Inc.

Pathway Therapeutics Inc.

Auckland Uniservices Limited

Cancer Research Campaign Technology Limited

Warner Lambert LLC

Development Finance Corporation of New Zeland

Development of Finance Corporation of New Zealand

Gordon William Rewcastle

William Alexander Denny

Alexander James Bridges

Graham John Atwell

Bruce Charles Baguley

David W Fry

Andrew Mark Thompson

Alan Kraker

Robert Frederick Meyer

Anna Giddens

Swarnalatha Akuratiya Gamage

Julie Ann Spicer

Moana Tercel

Michael David Kaufman

Jack Urquhart Flanagan

Kit Yee Tsang

Stephen Douglas Barrett

Brian Desmond Palmer

Howard D Showalter

Ellen Myra Dobrusin

Ho Huat Lee

Muriel Bonnet

Guo-Liang Lu

Jared Bruce John Milbank

John A Flygare

Haile Tecle

Brian Salvatore Safina

Thomas Pillow

BinQing Wei

Vishal Verma

Howard Daniel Hollis Showalter

Christian Miller

Graeme John Finlay

Anna Claire Giddens

Huifen Chen

Joseph Thomas Repine

James Bernard Kramer

Peter Laurence Toogood

James S Kaltenbronn

Andrew David White

Dennis Joseph McNamara

Binqing Wei

Douglas Scott Johnson

Daniel Fred Ortwine

John Quin, Iii

Daniele Marie Leonard

Roy Thomas Winters

Mark Stephen Plummer

Aurash B Shahripour

Jeremy Tyson Starr

Richard H Hutchings

Hamish Scott Sutherland

Stephen Michael Frazer Jamieson

Richard John Sciotti

Christina Maree Buchanan

Christopher Richardson

Shannon Leigh Black

Christopher Emil Whitehead

Peter Robin Shepherd

Andrew James Marshall

H D H Showalter

Thomas H Pillow

Disclosed are tricyclic heterocyclic compounds having kinase inhibitory activity, pharmaceutical compositions and kits comprising the compounds, and use of the compounds in the treatment of or in medicaments for the treatment of various diseases and conditions. In particular, disclosed are tricyclic heterocyclic compounds of the formula (I) having CSF-1R (c-FMS kinase) inhibitory activity and their use in the treatment of various diseases and conditions, such as those mediated by CSF-1R, including proliferative or neoplastic diseases and conditions, including cancers, and bone, inflammatory, and autoimmune diseases and conditions.

Tricyclic heterocyclic derivatives and uses thereof

The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.

1-(Chloromethyl)-2,3-dihydro-1H-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment

1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment

Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs. 

Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy

Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazoles of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs. 

Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy

Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents. 

Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents

The present invention relates to 5-substituted-4-(substituted)phenylamino-2-pyridone derivatives, pharmaceutical compositions and methods of use thereof.

5-substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives

Disclosed are compounds of Formulae (Ia), (Ib), (Ic), (Id) wherein: W is NH, S, SO, or SO; Ris (un)substituted aryl, (un)substituted heteroaryl, or (un)substituted carbocycle or heterocycle; Q is hydrogen or lower alkyl; Rand Rare the same or different and represent hydrogen, halogen, lower alkyl, lower alkoxy, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted arylalkyl or (un)substituted heteroarylalkyl; and Ris hydrogen, lower alkyl or an (un)substituted carbocyclic group containing from 3&#x2013;7 members, up to two of which members are optionally hetero atoms selected from oxygen and nitrogen; or Ris (un)substituted aryl, (un)substituted heteroaryl, (un)substituted arylalkyl or (un)substituted heteroarylalkyl. These compounds are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases. The present invention also provides a method of treating cell proliferative disorders. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula (I).

Pteridinones as kinase inhibitors

The present invention relates to oxygenated esters of 4-substituted-phenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.

N-(4 substituted phenyl)-anthranilic acid hydroxamate esters

The present invention provides novel 5-substituted tetralones of Formulas I, II, III, and IV and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme

5-substituted tetralones as inhibitors of ras farnesyl transferase

N-(4-substituted phenyl)-anthranilic acid hydroxamate esters

The present invention relates to oxygenated esters of 4-substituted-phenylamino benzhydroxamic acid derivatives, pharmaceutical compositions, and methods of use thereof.

Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family

Growing community of inventors

Auckland, New Zealand

Gordon William Rewcastle